Treatment breakdown for vulva cancers

Slides:



Advertisements
Similar presentations
The All Breast Cancer Report was published in October breastscreen/research.html#breast- cancer-report.
Advertisements

Variations in Cancer Surgery Across the East Midlands and North Trent EMPHIN Forum (Apr 2010) Carolynn Gildea Trent Cancer Registry.
WALES BREAST CANCER CLINICAL AUDIT (WBCCA) MDT DATA FOR PATIENTS DIAGNOSED in 2009, 2010 and 2011 YSBYTY MAELOR WREXHAM (BCUHB) MDT.
National Cancer Intelligence Network data usage 17 November 2015 – Veronique Poirier – Principal Cancer Analyst – NCIN.
WALES BREAST CANCER CLINICAL AUDIT (WBCCA) MDT DATA FOR PATIENTS DIAGNOSED in 2009, 2010 and 2011 CTUHB (Royal Glamorgan and Price Charles Hospitals) MDT.
National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.
How clinicians use data to make an impact on clinical outcomes Andrew Brodbelt Consultant Neurosurgeon and Clinical Director of Neurosurgery, The Walton.
South West Public Health Observatory South West Regional Public Health Group Opportunities for future analysis by SWPHO Sean McPhail South West Public.
Routes to Diagnosis of Cancer in London, Katherine Henson, NCRAS, Presentation for London Public Health Knowledge and Intelligence Network.
South West Public Health Observatory The changing casemix of prostate cancer patients and prostatectomies in the South West Sean McPhail.
Midland Cancer Network 2012 Clinical Performance Conference.
WALES BREAST CANCER CLINICAL AUDIT (WBCCA) MDT DATA FOR PATIENTS DIAGNOSED in 2009, 2010 and 2011 Llandough Hospital (Cardiff and Vale UHB) MDT.
How clinicians use data to make an impact on clinical outcomes Dr Mick Peake Clinical Lead, National Cancer Intelligence Network Consultant & Senior Lecturer.
A ssociation of Public Health Observatories Hospital Activity data Roy Maxwell SWPHO & Bristol University Dr Richard Wilson Sandwell PCT.
Variation in place of death from cancer: studies in South East England Elizabeth Davies, Peter Madden, Victoria Coupland, Karen Linklater, Henrik Møller.
South West Public Health Observatory South West Regional Public Health Group Impact of urological cancer, by stage at diagnosis Sean McPhail 1, David Gillatt.
Scottish Renal Cancer Forum National Meeting 31st March 2016 Renal cancer survival Period of diagnosis: Roger Black.
South West Public Health Observatory South West Regional Public Health Group Overview of Neuro-oncology in the South West Sean McPhail South West Public.
Alfredo Addeo Lung NSSG 15th November 2016
Oesophago–Gastric Cancer Audit
How clinicians use data to make an impact on clinical outcomes
Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.
Oesophago–Gastric Cancer
National Oesophago–Gastric Cancer Audit 2015.
Curative treatment rates for patients diagnosed with
Patterns of psychiatric hospital admission for schizophrenia and related psychosis in England: A retrospective cross-sectional survey Thompson A. D.¹,
WALES BREAST CANCER CLINICAL AUDIT (WBCCA) MDT DATA FOR PATIENTS DIAGNOSED in 2009, 2010 and 2011 Llandudno General Hospital (BCUHB) MDT.
Segmented analysis of prostate cancer pathway from referral to treatment: This work was carried out in partnership between the Transforming.
Oesophago–Gastric Cancer
Surgical Cancer Treatment
WALES BREAST CANCER CLINICAL AUDIT (WBCCA) MDT DATA FOR PATIENTS DIAGNOSED in 2009, 2010 and 2011 Singleton Breast Cancer (ABMUHB) MDT.
Behavioural Symptoms of Dementia
Oesophago–Gastric Cancer Audit
Ensuring variations in clinical practice are represented accurately in the new national cancer chemotherapy (SACT) programme Dr Ken Lloyd, Sue Forsey.
Dr James Carlton, Medical Adviser
Healthy London Partnership
Treatment breakdown for prostate cancers
Treatment breakdown for breast cancers
Treatment breakdown for NSCLC cancers
Schizophrenia Care for Adults in Hospitals
Treatment breakdown for salivary gland cancers
Treatment breakdown for kidney cancers
Treatment breakdown for liver cancers
Treatment breakdown for larynx cancers
Treatment breakdown for stomach cancers
Segmented analysis of the lung cancer median pathway from referral to treatment: This work was carried out in partnership between the Transforming.
Treatment breakdown for colon cancers
Treatment breakdown for oropharynx cancers
Treatment breakdown for bladder cancers
Treatment breakdown for oesophagus cancers
Treatment breakdown for pancreatic cancers
National Cancer Diagnosis Audit
Treatment breakdown for oral cavity cancers
Hannah Marder Cancer Manager UH Bristol
Treatment breakdown for uterine cancers
Treatment breakdown for rectum cancers
Treatment breakdown for SCLC cancers
Treatment breakdown for hypopharynx cancers
Treatment breakdown for cervical cancers
Treatment breakdown for ovary cancers
National Oesophago-Gastric Cancer Audit 2018 Annual Report: Slide set
Tuberculosis in Wales Annual Report 2018 Data to the end of 2017
Treatment breakdown for other head and neck cancers
2017/18 National Diabetes Audit Cambridgeshire and Peterborough CCG local summary Public Health Intelligence, Cambridgeshire and Peterborough : April 2019.
Comparing the multiple sources of cancer treatment data
THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018
Dataset Description Time Period Accident & Emergency
DRAFT Granta Data pack January 2019.
Tuberculosis in Wales Annual Report 2017 Data to the end of 2016
Representativeness of linked cancer registry and dispensed prescription data as compared with cancer registry data alone, by key patient and tumour characteristics.
Presentation transcript:

Treatment breakdown for vulva cancers This work has been produced as part of the Cancer Research UK - Public Health England Partnership. Contributors are listed at the end.

Methods 1) These slides present the numbers and percentages of tumours diagnosed in England in 2013 - 2015 recorded as receiving radiotherapy, chemotherapy or tumour resection. The results are presented by year, stage at diagnosis, age, sex, deprivation, ethnicity, and comorbidities. The stage distribution is presented, followed by  the treatment breakdown (independently and in combinations) for each variable. This work uses data collected by the NHS, as part of the care and support of cancer patients. Detail on methodology is described in the SOP and workbook (here) and summarised below: These proportions are unadjusted, so patterns may be caused by differences in stage, deprivation, age, sex, ethnicity, comorbidities or other factors, such as patient choice. Datasets used to capture treatment information include cancer registration data, the Systemic Anti-Cancer Therapy dataset (SACT), RadioTherapy DataSet (RTDS), and inpatient Hospital Episode Statistics (HES). A tumour resection is an attempt to surgically remove the whole of the primary tumour. Radiotherapy includes both curative and palliative teletherapy procedures, and excludes brachytherapy and contact radiotherapy. Chemotherapy includes both curative and palliative chemotherapy, and excludes hormonal therapy, and other supportive drugs such as zoledronic acid, pamidronate, and denosumab.

Methods 2) On the graphs which display combinations of treatments received, one of the categories is ‘Other care’. ‘Other care’ represents the group of patients who had no record of chemotherapy, tumour resection, or radiotherapy in the time frame assessed. This may include patients who received other treatments (such as hormonal therapy or management of symptoms), treatment outside of the time frame assessed, treatment in a private setting, or there may be data missing from the datasets used. The patient's Charlson comorbidity score was derived from Hospital Episodes Statistics (HES) and Cancer Registry data combined, and looks from 27 months to 3 months before the patient's cancer diagnosis. The patient’s age group was based on the age of the patient when they were diagnosed with the tumour. The patient’s income deprivation quintile was allocated by linking the patient’s postcode to their 2011 ONS census lower super output area (LSOA). This was then linked to the Ministry of Housing, Communities & Local Government 2015 income deprivation quintile for that LSOA. Treatments occurring in the period from 1 month before diagnosis to either 6, 9, 12, 15 or 18 months after diagnosis are displayed. The time period within which most patients' first course of treatment occurred varies by cancer site and treatment type. Therefore, an appropriate time period for each cancer site has been chosen using a data-driven approach in consultation with clinicians (see SOP for more information).

Summary of key results The display of treatments as combinations is more informative than where the treatments are displayed independently, as this reflects clinical practice. Stage: The pattern intuitively reflects clinical reality – most stage 1-3vulval cancers are resected, and it is encouraging to see that close to 40% of stage 4 receive resection. Adjuvant radiotherapy is standard for where there are nodal metastases. Among the stage 2 tumours, the 10% receiving chemoradiotherapy without surgery reflects when there is involvement of the urethra or anus. Age: The results show a decrease in use of tumour resection through the age groups, however there is an impressively high proportion of 80+ year olds receiving tumour resection only (56%), with the reduction of adjuvant treatments in the elderly likely reflecting multiple comorbidities. Deprivation: It is encouraging that deprivation status does not impact on treatment. Co-morbidity: The breakdown demonstrates less variation between the comorbidity score groups than for other gynaecological tumours, but 27% of those with Charlson comorbidity score 3+ likely receive no active treatment for (the majority of “other care” for vulval tumours), compared to 12% of those with Charlson comorbidity score 0, 15% of score 1, 16% of score 2.

Cohort for vulva cancers

By diagnosis year

By diagnosis year

By diagnosis year

By stage

By stage

By stage

By age

By age

By age

By deprivation quintile

By deprivation quintile

By deprivation quintile

By broad ethnic group

By broad ethnic group

By broad ethnic group

By comorbidity score

By comorbidity score

By comorbidity score

Acknowledgements Public Health England and Cancer Research UK would like to thank the following analysts who developed this workbook: Dr. Sean McPhail, Dr. Katherine Henson, Anna Fry, Becky White We would like to thank the following analysts who contributed to the work: Clare Pearson, Sabrina Sandhu, Carolynn Gildea, Jess Fraser, Michael Wallington, Cong Chen We would also like to thank the following clinicians and analysts who offered feedback on this workbook or helped improve the tumour resections data featured in it: Dr. Andy Nordin, Mr. Kieran Horgan, Mr. Ravinder Vohra, Prof. Mick Peake, Prof. Eva Morris, Mr. Keith Roberts, Mr. Graham Putnam, Dr. Roland Valori, Prof. Hemant Kocher, Mr. Roger Kockelbergh, Prof. Paul Finan